Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test. (November 2014)

• Record Type: Journal Article
• Authors: Dupont, Benoît; Mariotte, Delphine; Clarisse, Bénédicte; Galais, Marie-Pierre; Bouhier-Leporrier, Karine; Grellard, Jean-Michel; Le Mauff, Brigitte; Reimund, Jean-Marie; Gervais, Radj
• Is Part Of: Future oncology. Volume 10:Number 14(2014)
• Page Start: 2133
• Page End: 2140
• Publication Date: 2014-11
• Subjects: anaphylaxis -- anti-IgE antibodies -- cetuximab -- colonic neoplasms -- head and neck neoplasms -- hypersensitivity; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.153
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : Aim: To describe the factors associated with a high risk of a hypersensitivity reaction to cetuximab.Patients & methods: We retrospectively studied a cohort of patients living in Normandy (France) treated with cetuximab.Results: Among the 229 treated patients, 24 (10.5%) had a hypersensitivity reaction to cetuximab, including 11 grade 3–5 reactions. Detection of anti-cetuximab IgE could be performed in 108 patients. Anti-cetuximab IgE was found in 13 of 17 patients (76.5%) who had a hypersensitivity reaction to cetuximab compared with 17 of 91 control patients (18.7%; adjusted odds ratio: 14.99; 95% CI: 3.59–62.63). No clinical criteria predicted the risk of allergy to cetuximab.Conclusion: Anti-cetuximab IgE may help physicians identify patients at risk of a hypersensitivity reaction to cetuximab.